Table 2.

Reasons for discontinuation of secukinumab treatment in PsA patients.

Causes for SEC discontinuation
SEC discontinuation (any), n (%) [N]	51 (29) [178]
Primary failure, n (%) [N]	23 (45) [51]
Secondary failure, n (%) [N]	18 (35) [51]
Intolerance, n (%) [N]	1 (2) [51]
Adverse events, n (%) [N]	5 (10) [51]
Loss of follow-up, n (%) [N]	1 (2) [51]
Patient decision, n (%) [N]	1 (2) [51]
Other medical reasons, n (%) [N]	2 (4) [51]

SEC, Secukinumab.